New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
09:37 EDTTCK, THOR, CFN, IRG, PNG, NUAN, PLD, IT, ITW, OSK, DE, CMI, CYS, BG, TEVA, SKUL, RVBD, ANROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Alpha Natural (ANR) downgraded to Fair Value from Buy at CRT Capital... Riverbed (RVBD) downgraded to Market Perform from Outperform at FBR Capital... Skullcandy (SKUL) downgraded to Neutral from Buy at Roth Capital... Teva (TEVA) downgraded to Hold from Buy at Canaccord... Bunge (BG) downgraded to Hold from Strong Buy at Feltl... CYS Investments (CYS) downgraded to Neutral from Buy at Compass Point... Deere (DE) downgraded to Buy from Strong Buy at ISI Group... Cummins (CMI) downgraded to Buy from Strong Buy at ISI Group.. Oshkosh (OSK) downgraded to Buy from Strong Buy at ISI Group... Illinois Tool Works (ITW) downgraded to Buy from Strong Buy at ISI Group... Gartner (IT) downgraded to Neutral from Overweight at Piper Jaffray... ProLogis (PLD) downgraded to Hold from Buy at Stifel Nicolaus... Nuance (NUAN) downgraded to Hold from Buy at Stifel Nicolaus... CYS Investments (CYS) downgraded to Hold from Buy at Stifel Nicolaus... PAA Natural Gas Storage (PNG) downgraded to Market Perform from Outperform at Raymond James... Ignite Restaurant (IRG) downgraded to Outperform from Strong Buy at Raymond James... CareFusion (CFN) downgraded to Outperform from Buy at CLSA... Riverbed (RVBD) downgraded to Neutral from Buy at Lazard Capital... Thoratec (THOR) downgraded to Market Perform from Outperform at Northland Securities... Teck Resources (TCK) downgraded to Neutral from Overweight at JPMorgan.
News For ANR;RVBD;SKUL;TEVA;BG;CYS;CMI;DE;OSK;ITW;IT;PLD;NUAN;PNG;IRG;CFN;THOR;TCK From The Last 14 Days
Check below for free stories on ANR;RVBD;SKUL;TEVA;BG;CYS;CMI;DE;OSK;ITW;IT;PLD;NUAN;PNG;IRG;CFN;THOR;TCK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 7, 2014
13:55 EDTTEVATeva won't be meaningfully hurt soon by new Copaxone filing, says BMO Capital
After Teva (TEVA) confirmed that it received the first paragraph IV notice for the 3x per week version of its Copaxone drug from Dr. Reddy's (RDY), BMO Capital said it had expected companies to seek to market a generic version of the latest Copaxone formulation, but was surprised that Dr. Reddy's took this action. The firm notes that Teva's decision to file a lawsuit against Dr. Reddy over the application will trigger a 30 month stay of approval of the generic version,. BMIO Capital says that investors should keep this issue on their radar, but the firm does not expect Teva to be meaningfully hurt in the near-term by this development. It keeps an Outperform rating on Teva.
12:14 EDTTHOROn The Fly: Midday Wrap
Subscribe for More Information
12:06 EDTTEVATeva will continue to defend COPAXONE intellectual property rights
Teva (TEVA) confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE 40 mg/mL product from Dr. Reddy’s Laboratories (RDY). Teva will continue to vigorously defend its COPAXONE intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of FDA approval of Dr. Reddy’s ANDA. COPAXONE 40 mg/mL is protected by two Orange Book patents that expire in 2030.
10:20 EDTTEVAMylan says litigation ins ongoing in India regarding Teva
Mylan (MYL) said that it expects Teva's (TEVA) efforts to seek an injunction will "as ineffective as it was in U.S. courts." The company said it will not provide further comment on the matter. Mylan said it will also postpone its 2014 Investor Day due to the ongoing nature of the Abbott (ABT) transaction. It expects its fully realized savings and profit from new products will not be realized till 2015. Comments taken from Q2 earnings conference call.
10:15 EDTTHORThoratec drops sharply after results, guidance, downgrades
Subscribe for More Information
10:00 EDTTHOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTANR, ITWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:08 EDTTHOROn The Fly: Pre-market Movers
Subscribe for More Information
08:46 EDTANRAlpha Natural shares attractive at current levels, says Sterne Agee
Subscribe for More Information
08:20 EDTTHORThoratec downgraded to Neutral from Buy at BTIG
Subscribe for More Information
08:08 EDTTHORThoratec price target lowered to $35 from $41 at Oppenheimer
Oppenheimer cut its price target on Thoratec after the company reported lower than expected revenue and lowered its sales guidance, but reported higher than expected EPS. However, the firm says it has seen significant lumpiness in Thoratec's market before and expects investors' focus to shift to the company's new HeartMate III product. The firm keeps an Outperform rating on the shares.
08:04 EDTITWIllinois Tool Works upgraded to Buy from Neutral at ISI Group
ISI Group upgraded Illinois Tool Works to Buy citing recent share weakness, year-to-date machinery sector underperformance, continued restructuring benefits and high operating leverage. Price target to $92 from $90.
07:56 EDTTHORThoratec downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
07:46 EDTNUANNuance August volatility elevated into Q3 and outlook
Nuance August call option implied volatility is at 67, September is at 42, January is at 34; compared to its 26-week average of 38 according to Track Data, suggesting large near term price movement into the expected release of Q3 on August 11.
07:42 EDTANRAlpha Natural upgraded to Neutral at UBS
Subscribe for More Information
07:42 EDTTHORThoratec price target lowered to $28 from $39 at Canaccord
Subscribe for More Information
07:31 EDTTHORThoratec long-term opportunity remains intact, says Leerink
Subscribe for More Information
06:50 EDTANRAlpha Natural upgraded at UBS
Subscribe for More Information
06:25 EDTTHORThoratec downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
05:37 EDTTHORThoratec downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Thoratec to Neutral citing the weaker LVAD market and limited visibility following the company's Q2 results. The firm lowered its price target for shares to $28 from $38. Goldman keeps a Sell rating on peer HeartWare (HTWR) and lowered its price target on the name to $73 from $75.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use